Search results
Showing 1 to 4 of 4 results for ibrance
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.
NICE approves routine use of drug combination for advanced breast cancer
Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today (23 September 2022).
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.